2013

Kareus initiates phase I trial in Alzheimer’s disease

Friday, January 4, 2013

Kareus Therapeutics, a private biotechnology company focused on unmet treatment of age-related and chronic diseases, has initiated a phase I clinical study following the Investigational New Drug (IND) approval from the FDA for the development of KU-046, a first-in-class disease modifying new chemical entity discovered for the treatment of Alzheimer’s disease using Kareus’ proprietary bioenergetics and KARLECT platforms.

[Read More]

Heffernan and Koch join Lilly’s autoimmune team

Friday, January 4, 2013

Global pharmaceutical company Eli Lilly has appointed Michael P. Heffernan, M.D., a nationally recognized expert in complex medical dermatology, psoriasis and clinical trials, as a distinguished medical fellow of its autoimmune team. Alisa E. Koch, M.D., a rheumatologist who has won numerous academic awards for her extensive work in rheumatoid arthritis, also joined the team as senior medical fellow.

[Read More]

Labrys Biologics secures $31M financing, acquires antibody for chronic migraine from Pfizer

Friday, January 4, 2013

Labrys Biologics, a development stage biotechnology company focused on chronic migraines, has completed a $31 million Series A financing from four leading venture capital firms: venBio, Canaan Partners, InterWest Partners and Sofinnova Ventures. With the close of the financing, Labrys has acquired RN-307 from Pfizer Inc., a phase II ready anti-CGRP humanized monoclonal antibody for the treatment of chronic migraine. In addition, Steven P. James has been appointed president and CEO.

[Read More]

Government backs small business with $8.1M funding boost

Friday, January 4, 2013

The U.K. government is holding two new competitions, with a total of up to $8.1 million in funding, for small businesses who have ideas that can improve the experience for older people at the end of their life or improve the experience for people with mental health illnesses.

[Read More]

Biogen Idec to discontinue development of ALS drug

Friday, January 4, 2013

Weston, Mass.-based Biogen Idec has decided to discontinue development of dexpramipexole in amyotrophic lateral sclerosis (ALS), after top-line results of EMPOWER, its phase III trial, did not meet its primary endpoint, a joint rank analysis of function and survival, and no efficacy was seen in the individual components of function or survival.

[Read More]